Compare ADMA Biologics Inc (ADMA) vs IAC/Interactivecorp (PPLI) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

PPLI trades at $47.62, up 1.86% today, showing bullish technical momentum with moving averages supporting the uptrend. However, the stock has missed earnings expectations for three consecutive quarters, with Q1 2026 EPS of -$0.94 falling short of the -$0.37 estimate. Despite a high gross margin of 66.49%, net income margin remains thin at 1.75%, and cash flow turned negative in 2025 with a net outflow of $820.42 million. Analyst consensus remains positive with a $55.40 price target, though recent news questions valuation after a rally.

The outlook is mixed: strong analyst buy ratings and a discounted P/B of 0.77 suggest upside potential, but persistent earnings misses and negative cash flow pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges. Investors should weigh the bullish technical setup against fundamental weaknesses and high debt levels before committing capital.